^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

Preclinical evaluation of LX-086, a small molecule as a selective inhibitor of PI3K.

Published date:
05/28/2020
Excerpt:
LX-086 showed antitumor efficacy in HER2+/HR+, PIK3CA amplified breast cancer BT-474 CDX model (TGI = 106% @40 mpk, QD), as well as in the HER2-/HR+, PIK3CA H1047R breast cancer T47D CDX model (TGI = 84.7%@40 mpk, QD) and PIK3CA H1047R ovarian cancer SK-OV-3 CDX model (TGI = 69.2%@40 mpk, QD). 
DOI:
10.1200/JCO.2020.38.15_suppl.e15662